About this trial The purpose of this study is to determine whether nivolumab + brentuximab vedotin, followed by brentuximab vedotin + bendamustine for participants with a suboptimal response, is safe and effective in the treatment of classic Hodgkin lymphoma (cHL) in children, adolescents, and young adults after failure of first line therapy. Eligible patients from … Continue reading CheckMate 744